Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New…
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price75.86 USD
Fair value68.22
Ethical score70.0/100
RatingQUALITY, FULLY VALUED
Our investment reviews on this name
2026-10-11Read Accumulation70.46+7.7% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown70.46+7.7% to today Accumulation gives way to Markdown
2026-09-04Read Accumulation72.95+4.0% to today ✓Markup gives way to Accumulation after a 19% rise in 9 weeks
2026-07-02Read Markup61.53+23.3% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Lonza Group AG holds its Accumulation at $75.86. Consolidating, no directional conviction, held for 367 days.
As held on the ledger · 2026-10-28
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 367 days
Price at the screen
$75.86
Valuation
37.15 trailing · 27.17 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.81
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
10.82%
Below 33%
Interest-bearing debt is just 10.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.66%
Below 33%
Cash held in interest-bearing accounts and securities is 1.7% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.66%
Below 5%
Only 0.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Lonza clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 11%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LZAGY's ethical verdict changes
Today LZAGY passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads QUALITY, FULLY VALUED: it trades above our $68.22 fair value estimate, moderate competitive moat, 11.20% revenue growth.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. The price runs 10.1% above the base estimate.
Third-party analyst targets: 3 covering, consensus None. The average target sits +2% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Swiss CDMO priced right at fair value
Picture a Swiss factory turning raw biotech ideas into real medicines for clients across the globe. Lonza does exactly that as a contract manufacturer, yet the shares sit only a whisker below our fair value with a slim one percent margin of safety.
We pass because the business is overvalued on a forward multiple of 24.7 times while posting a negative four percent profit margin and a modest ten percent return on equity. A moderate moat and clean ethical screen are not enough to offset the lack of real discount.
The main risks are thin returns and any slowdown in biotech outsourcing that could keep margins under pressure. Three analysts see a median target of seventy nine dollars, yet that alone does not create a compelling case.
The risks · The things to watch: its business and earnings are exposed to Switzerland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LZAGY trades on PNK (the company is based in Switzerland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-26Accumulation$72.81+3.3%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (3 analysts) rates it buy, with a mean price target of $82.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (3 analysts) rates it buy, with a mean price target of $82.
2026-10-02Markdown · changed$70.46-3.4%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (3 analysts) rates it buy, with a mean price target of $82.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (3 analysts) rates it buy, with a mean price target of $82.
2026-08-05Markup$68.24+10.9%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (3 analysts) rates it buy, with a mean price target of $82.
2026-07-18Markup$61.53+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (3 analysts) rates it buy, with a mean price target of $82.
2026-07-03Markup$61.53+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$61.53Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
